Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory disease. New treatment strategies that circumvent...

Descripción completa

Detalles Bibliográficos
Autores principales: McCorkle, J. Robert, Gorski, Justin W., Liu, Jinpeng, Riggs, McKayla B., McDowell, Anthony B., Lin, Nan, Wang, Chi, Ueland, Frederick R., Kolesar, Jill M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336885/
https://www.ncbi.nlm.nih.gov/pubmed/34347777
http://dx.doi.org/10.1371/journal.pone.0254205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336885/
https://www.ncbi.nlm.nih.gov/pubmed/34347777
http://dx.doi.org/10.1371/journal.pone.0254205

Ejemplares similares